Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.

Pharmacotherapy - 1 Jan 2026

Cheng Siang-Hao, Novelli Enrico M, Kang Hyeun Ah, Newman Terri V, Suh Kangho

Abstract excerpt

BACKGROUNDS: Hydroxyurea (HU) remains underutilized in adults with sickle cell disease (SCD) despite proven benefits. Current HU guidelines primarily target sickle cell anemia (SCA), overlooking other genotypes. OBJECTIVES: This study examined HU utilization patterns across genotypes among adults considered to have moderate to severe SCD manifestations by the 2014 National Heart, Lung, and Blood Institute (NHLBI)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Cohort Studies
Share to SCD gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hydroxyurea

Share to Severity of Illness Index

Source

Open in PubMed Open full text

Identifiers

PMID: 41531305
DOI: 10.1002/phar.70099
PMCID: PMC12800872

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.PMID 41531305Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.Semantic proximity Read ↗

Sickle Cell Disease.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Demographics and outcomes of hemoglobin genotype in hospitalized patients with COVID-19 and sickle cell disease in the United States.Semantic proximity Read ↗

Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemiaSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in Brazil: retrospective cohort study of real-world dataSemantic proximity Read ↗

Clinical Spectrum of Sickle Cell Disease and COVID-19: Laboratory and Clinical Factors Associated with Morbidity and MortalitySemantic proximity Read ↗

Current and emerging treatments for sickle cell diseaseSemantic proximity Read ↗

CureSCi Metadata Catalog—finding and harmonizing studies for secondary analysis of hydroxyurea use for sickle cell diseaseSemantic proximity Read ↗

Prevalence and Significance of Elevated Cardiac Enzymes among Sickle Cell Disease Patients at King Abdulaziz University HospitalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.